Aspirin Continuation

Phase 3Small molecule

TTao Liu

Aspirin Continuation is one of 94 small molecule programs targeting Hematoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HematomaActive, not recruiting

Coronary Artery BypassActive, not recruiting

PreeclampsiaActive, not recruiting

HematomaPreclinical

Active, not recruiting

Coronary Artery BypassPreclinical

Active, not recruiting

PreeclampsiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

148 competitors in Coronary Artery Bypass

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Phase 3

1 2

Crestor

AstraZeneca

Phase 3

1 3

Cyklokapron

AAmring

Phase 3

3 4

Effient

CCosette Pharmaceuticals, Inc.

Phase 3

1 5

Bactroban

PPadagis LLC

Phase 3

1 6

Aggrastat

MMedicure

Phase 3

1 7

Arixtra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 8

Glargine Insulin

AstraZeneca

Phase 3

1 9

Iron Sulphate

PPierre Fabre Pharma GmbH

Phase 3

1 10

Low-Dose Aspirin

PPharmaEssentia Japan K.K.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ARecruiting

Hematoma

NCT07240454

Clinical

Trials by Indication[1]

Hematoma1 trial

Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma

Recruiting·TTao Liu·N/A·NCT07240454·143 enrolled

Coronary Artery Bypass1 trial

Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery

Completed·SSeoul National University Hospital·N/A·NCT02209909·48 enrolled

Preeclampsia1 trial

Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia

Recruiting·FFANG HE·Phase 3·NCT06111079·1,800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Aspirin Continuation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aspirin Continuation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aspirin Continuation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tao Liu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTao Liu

Aspirin Continuation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Hematoma1 trial

Coronary Artery Bypass1 trial

Preeclampsia1 trial

References

Drug Info

Quick Facts

Related News